NASDAQ:REGN Regeneron Pharmaceuticals (REGN) Stock Price, News & Analysis $1,052.25 +18.02 (+1.74%) (As of 07/8/2024 ET) Add Compare Share Share Today's Range$1,038.14▼$1,054.6050-Day Range$890.66▼$1,071.1952-Week Range$688.52▼$1,081.17Volume366,178 shsAverage Volume436,890 shsMarket Capitalization$115.95 billionP/E Ratio31.09Dividend YieldN/APrice Target$1,027.55 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Regeneron Pharmaceuticals alerts: Email Address Regeneron Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.77 Rating ScoreUpside/Downside2.3% Downside$1,027.55 Price TargetShort InterestBearish1.68% of Shares Sold ShortDividend StrengthN/ASustainability-2.69Upright™ Environmental ScoreNews Sentiment0.53Based on 23 Articles This WeekInsider TradingSelling Shares$62.51 M Sold Last QuarterProj. Earnings Growth8.70%From $37.23 to $40.47 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.90 out of 5 starsMedical Sector185th out of 876 stocksPharmaceutical Preparations Industry74th out of 416 stocks 2.4 Analyst's Opinion Consensus RatingRegeneron Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.77, and is based on 16 buy ratings, 4 hold ratings, and 1 sell rating.Amount of Analyst CoverageRegeneron Pharmaceuticals has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Regeneron Pharmaceuticals' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted1.68% of the outstanding shares of Regeneron Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverRegeneron Pharmaceuticals has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in Regeneron Pharmaceuticals has recently increased by 5.71%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldRegeneron Pharmaceuticals does not currently pay a dividend.Dividend GrowthRegeneron Pharmaceuticals does not have a long track record of dividend growth. Previous Next 2.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRegeneron Pharmaceuticals has received a 8.96% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Aflibercept", "Casirivimab and imdevimab", and "Alirocumab" products. See details.Environmental SustainabilityThe Environmental Impact score for Regeneron Pharmaceuticals is -2.69. Previous Next 3.1 News and Social Media Coverage News SentimentRegeneron Pharmaceuticals has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 23 news articles for Regeneron Pharmaceuticals this week, compared to 15 articles on an average week.Search Interest16 people have searched for REGN on MarketBeat in the last 30 days. This is an increase of 60% compared to the previous 30 days.MarketBeat Follows17 people have added Regeneron Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 89% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Regeneron Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $62,514,142.00 in company stock.Percentage Held by InsidersOnly 7.48% of the stock of Regeneron Pharmaceuticals is held by insiders.Percentage Held by Institutions83.31% of the stock of Regeneron Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Regeneron Pharmaceuticals' insider trading history. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Regeneron Pharmaceuticals are expected to grow by 8.70% in the coming year, from $37.23 to $40.47 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Regeneron Pharmaceuticals is 31.09, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 143.01.Price to Earnings Ratio vs. SectorThe P/E ratio of Regeneron Pharmaceuticals is 31.09, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 169.50.Price to Earnings Growth RatioRegeneron Pharmaceuticals has a PEG Ratio of 2.14. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioRegeneron Pharmaceuticals has a P/B Ratio of 4.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Regeneron Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Freeport SocietyBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend into chaos.Click here now to see my urgent election warning. About Regeneron Pharmaceuticals Stock (NASDAQ:REGN)Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.Read More REGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart REGN Stock News HeadlinesJuly 3, 2024 | insidertrades.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Director Sells $105,924.00 in StockJune 26, 2024 | insidertrades.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Director Bonnie L. Bassler Sells 756 SharesJuly 9, 2024 | Paradigm Press (Ad)Bitcoin’s Biggest Year Yet2024 is set to be a historic year for Bitcoin. It’s all thanks to three major catalysts that I reveal in my newest video.June 18, 2024 | insidertrades.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Director Sells $1,596,400.00 in StockJune 14, 2024 | insidertrades.comInsider Selling: Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) CEO Sells 9,064 Shares of StockJune 11, 2024 | insidertrades.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) CEO Leonard S. Schleifer Sells 787 SharesJuly 8 at 8:00 AM | fool.com3 No-Brainer Stocks to Buy in JulyJuly 8 at 6:00 AM | investorplace.com3 Pharma Stocks Already Ushering in the Next Biotech BoomJuly 9, 2024 | Paradigm Press (Ad)Bitcoin’s Biggest Year Yet2024 is set to be a historic year for Bitcoin. It’s all thanks to three major catalysts that I reveal in my newest video.July 7 at 2:59 PM | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGNJuly 5, 2024 | investors.comSwing Trading Regeneron Stock Shows How To Bob And WeaveJuly 5, 2024 | americanbankingnews.comRegeneron Pharmaceuticals (NASDAQ:REGN) Stock Price Down 3.2% After Insider SellingJuly 4, 2024 | investorplace.com7 High Priced Stocks That Would Benefit From a Stock SplitJuly 4, 2024 | americanbankingnews.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) EVP Sells $1,190,564.07 in StockJuly 3, 2024 | globenewswire.comDupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPDJuly 3, 2024 | globenewswire.comPress Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPDJuly 2, 2024 | gurufocus.comInsider Sale: Director Arthur Ryan Sells Shares of Regeneron Pharmaceuticals Inc (REGN)July 2, 2024 | prnewswire.comKuehn Law Encourages Investors of Regeneron Pharmaceuticals, Inc. to Contact Law FirmSee More Headlines Receive REGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today7/09/2024Next Earnings (Confirmed)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:REGN CUSIP75886F10 CIK872589 Webwww.regeneron.com Phone(914) 847-7000Fax914-347-2113Employees13,450Year Founded1988Price Target and Rating Average Stock Price Target$1,027.55 High Stock Price Target$1,229.00 Low Stock Price Target$720.00 Potential Upside/Downside-2.3%Consensus RatingModerate Buy Rating Score (0-4)2.77 Research Coverage22 Analysts Profitability EPS (Most Recent Fiscal Year)$33.85 Trailing P/E Ratio31.09 Forward P/E Ratio28.26 P/E Growth2.14Net Income$3.95 billion Net Margins29.45% Pretax Margin30.85% Return on Equity16.83% Return on Assets13.16% Debt Debt-to-Equity Ratio0.10 Current Ratio5.27 Quick Ratio4.51 Sales & Book Value Annual Sales$13.12 billion Price / Sales8.84 Cash Flow$44.03 per share Price / Cash Flow23.90 Book Value$236.63 per share Price / Book4.45Miscellaneous Outstanding Shares110,190,000Free Float101,944,000Market Cap$115.95 billion OptionableOptionable Beta0.13 Social Links 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Leonard S. Schleifer M.D. (Age 71)Ph.D., Co-Founder, President, CEO & Co-Chairman Comp: $8.18MDr. George D. Yancopoulos M.D. (Age 64)Ph.D., Co-Founder, President, Chief Scientific Officer & Co-Chairman Comp: $7.76MDr. Andrew J. Murphy Ph.D. (Age 65)Executive Vice President of Research Comp: $1.68MMr. Daniel P. Van Plew (Age 51)Executive VP and GM of Industrial Operations & Product Supply Comp: $2.01MMr. Christopher R. Fenimore CPA (Age 53)Senior VP of Finance & CFO Ms. Patrice GiloolySenior Vice President of Quality Assurance & OperationsMr. Bob McCowanSenior VP of IT & Chief Information OfficerMr. Ryan CroweSenior Vice President of Investor Relations & Strategic AnalysisMr. Joseph J. LaRosa (Age 65)Executive VP, General Counsel & Secretary Comp: $1.75MMs. Melissa LoznerSenior VP & Chief Compliance OfficerMore ExecutivesKey CompetitorsAllerganNYSE:AGNAmgenNASDAQ:AMGNVertex PharmaceuticalsNASDAQ:VRTXGilead SciencesNASDAQ:GILDAlexion PharmaceuticalsNASDAQ:ALXNView All CompetitorsInsiders & InstitutionsBoston Common Asset Management LLCSold 2,009 shares on 7/8/2024Ownership: 0.029%Woodstock CorpBought 397 shares on 7/8/2024Ownership: 0.004%Quent Capital LLCBought 21 shares on 7/8/2024Ownership: 0.000%Versant Capital Management IncBought 37 shares on 7/8/2024Ownership: 0.000%DNB Asset Management ASBought 1,196 shares on 7/5/2024Ownership: 0.029%View All Insider TransactionsView All Institutional Transactions Should I Buy Regeneron Pharmaceuticals Stock? REGN Pros and Cons Explained Pros Here are some ways that investors could benefit from investing in Regeneron Pharmaceuticals, Inc.: Regeneron Pharmaceuticals has a strong track record of developing innovative medicines for various diseases, showcasing a commitment to research and development. The company's stock price has shown consistent growth, reaching a 12-month high of $1,042.66, indicating positive investor sentiment. Regeneron Pharmaceuticals reported a net margin of 29.45% and a return on equity of 16.83%, demonstrating strong financial performance. Analysts have issued mostly positive ratings for the company, with an average rating of "Moderate Buy" and an average price target of $991.18, suggesting potential for stock price appreciation. Institutional investors and hedge funds have been increasing their stakes in Regeneron Pharmaceuticals, indicating confidence in the company's future growth prospects. Cons Investors should be bearish about investing in Regeneron Pharmaceuticals, Inc. for these reasons: One research analyst has issued a sell rating for the stock, indicating some concerns about the company's performance or future outlook. Regeneron Pharmaceuticals missed analysts' consensus estimates for earnings per share in the latest quarter, which could raise doubts about its ability to meet financial expectations. The company's price-to-earnings ratio of 30.62 and PEG ratio of 2.14 may suggest that the stock is currently overvalued compared to its earnings growth potential. While the stock has shown growth, the current market conditions or industry challenges could impact future performance and stock price stability. Investors should consider the company's debt-to-equity ratio of 0.10 and other financial ratios to assess the level of financial risk associated with investing in Regeneron Pharmaceuticals. These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, July 2, 2024. Please send any questions or comments about these Regeneron Pharmaceuticals pros and cons to contact@marketbeat.com. REGN Stock Analysis - Frequently Asked Questions How have REGN shares performed this year? Regeneron Pharmaceuticals' stock was trading at $878.29 at the start of the year. Since then, REGN stock has increased by 19.8% and is now trading at $1,052.25. View the best growth stocks for 2024 here. How were Regeneron Pharmaceuticals' earnings last quarter? Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) issued its quarterly earnings data on Thursday, May, 2nd. The biopharmaceutical company reported $7.97 earnings per share for the quarter, missing analysts' consensus estimates of $8.46 by $0.49. The biopharmaceutical company had revenue of $3.15 billion for the quarter, compared to the consensus estimate of $3.19 billion. Regeneron Pharmaceuticals had a net margin of 29.45% and a trailing twelve-month return on equity of 16.83%. What is Leonard S. Schleifer's approval rating as Regeneron Pharmaceuticals' CEO? 423 employees have rated Regeneron Pharmaceuticals Chief Executive Officer Leonard S. Schleifer on Glassdoor.com. Leonard S. Schleifer has an approval rating of 87% among the company's employees. Does Regeneron Pharmaceuticals have any subsidiaries? Regeneron Pharmaceuticals subsidiaries include Eastside Campus Holdings LLC, Loop Road Holdings LLC, Old Saw Mill Holdings LLC, OSMR Holdings, Regeneron Assurance Inc., Regeneron Atlantic Holdings, Regeneron Belgium BV, and more. Who are Regeneron Pharmaceuticals' major shareholders? Top institutional investors of Regeneron Pharmaceuticals include DNB Asset Management AS (0.03%), Boston Common Asset Management LLC (0.03%), Massmutual Trust Co. FSB ADV and Woodstock Corp. Insiders that own company stock include George Yancopoulos, Leonard S Schleifer, Neil Stahl, Andrew J Murphy, Joseph J Larosa, Robert E Landry, Plew Daniel P Van, Arthur F Ryan, Christopher R Fenimore, Marion Mccourt, Joseph L Goldstein, Marc Tessier-Lavigne, Christine A Poon, Michael S Brown, Bonnie L Bassler, Huda Y Zoghbi, N Anthony Coles, P Roy Vagelos and George L Sing. View institutional ownership trends. How do I buy shares of Regeneron Pharmaceuticals? Shares of REGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Regeneron Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ) and Walt Disney (DIS). This page (NASDAQ:REGN) was last updated on 7/9/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredYoung billionaire opens the door for millions of AmericansYou can now profit from a catalog of 11 inventions that will likely make their way into millions of U.S. house...Porter & Company | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredGrab Your Free Bitcoin Today!And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a v...Crypto Swap Profits | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | SponsoredTrump’s Gift Could Unleash $51 Billion in New WealthIn January 2021, Donald Trump silently rolled out a special gift to the American public… One that top house...Wealthpin Pro | SponsoredMissed NVDA? Buy this AI stock NOWAfter Nvidia's record-breaking earnings surge, Wall Street is now selling the stock at the fastest pace in sev...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regeneron Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Regeneron Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
